• Re-experiencing, e.g. recurrent unwanted intrusive memories, distressing dreams, flashbacks, distress at reexposure.
• Avoidance of stimuli associated with the trauma behaviours, e.g. the avoidance of distressing memories associated with the traumatic event or avoidance of external reminders.
• Negative alteration in cognitions and mood associated with the traumatic event, e.g. impairment in recalling important aspects of the trauma, negative thoughts and assumptions about oneself or the world, negative beliefs about the causes or consequences of the traumatic event, diminished interest or participation in significant activities, feeling of detachment from others, inability to experience positive emotions. • Arousal symptoms, e.g. hypervigilance, insomnia, irritability, reckless or self-destructive behaviour, problems concentrating. The development and maintenance of PTSD is most likely the product of an interaction of different factors. Although, current evidence alone cannot explain the complexity underlying PTSD, it is clear that multiple and interconnected systems are involved (Kelmendi 2016; Koch 2014; Lee 2016; Pitman 2012) , and although psychological mechanisms are involved, the disorder has a distinct biological profile (Besnard 2012; Nickerson 2013) . Appendix 1 presents a summary of the main evidence related to the biological profile of PTSD.
Description of the intervention
Interventions for preventing the development of PTSD can be divided into two main categories: psychosocial and pharmacological. Although this review focuses on the latter, several other publications have examined and reviewed the former (Bryant 2007; Forneris 2013; Kearns 2012; Qi 2016; Roberts 2010; Rose 2002) .
With respect to pharmacological interventions, drugs belonging to different classes have been examined by means of randomised clinical trials, and some reviews have already been published (Amos 2014; Sijbrandij 2015) . It should be noted that the mechanisms underlying the onset of the disorder are likely to be different from the ones maintaining it, and therefore some of the interventions proposed to prevent the onset of the disorder differ from the interventions for treatment.
Glucocorticoids are synthetic analogues of hormones involved in immunity and stress response. They can be administered in several ways including oral, intravenous and intramuscular. Depending on the purpose, a treatment course can last from a single shot to several days. The trials testing steroids for PTSD prevention have used either single dose administration or a course of a few days in individuals with severe physical conditions (Delahanty 2013; Schelling 2001; Weis 2006) . Hydrocortisone, along with some other steroids, is also included in the World Health Organization (WHO) Model List of Essential Medicines (WHO 2017), and therefore expected to be commonly available in several global contexts. Propranolol is a beta blocker, primarily used for long-term treatment in cardiology. Some trials have tested it on a three-week time span for PTSD prevention (Hoge 2012; Pitman 2002; Stein 2007) . Propranolol is also included in the WHO Model List of Essential Medicines (WHO 2017) . A small trial has investigated a short course of temazepam, which belongs to the class of benzodiazepines (common anxiolytic drugs), but found an increase of PTSD onset rather than a decrease (Mellman 2002) . Recently, there is growing interest in oxytocin, an endogenous hormone involved in sociability and stress regulation (Qi 2016), an early trial investigated oxytocin administered in a single intranasal dose (van Zuiden 2017). Escitalopram is a selective serotonin reuptake inhibitor (SSRI) antidepressant, and although this class has yielded good results in PTSD treatment, there is uncertainty whether SSRIs are effective in reducing the incidence of PTSD (Shalev 2012). Gabapentin, an anticonvulsant with anxiolytic properties and a benign side effect profile, has been included in trials of PTSD prevention (Stein 2007) . Opioids have been proposed too, for example a large retrospective study on USA soldiers with combat injury, found an association between morphine administration and lower PTSD incidence (Holbrook 2010).
How the intervention might work
The biological features of PTSD provide several possible targets for the pharmacological prevention of PTSD. Different rationales can explain the efficacy of the investigated drugs.
Glucocorticoids
Glucocorticoids are involved in both hormonal stress response and memory formation. The hypothalamicpituitary-adrenal (HPA) axis has long been a focus in PTSD investigations, and a role for hydrocortisone in facilitating extinction learning has been hypothesised (Hruska 2014). In a rodent model a negative association has been found between a high dose of steroids and prevalence of PTSD-like behaviour in rats exposed to predator scent stress (Cohen 2008), and coherent results were found in a morphological study (Zohar 2011) . There is also epidemiologic evidence that lower urinary cortisol levels in the immediate aftermath of the trauma are associated with future PTSD symptoms (Delahanty 2000; McFarlane 1997) .
Beta blockers
A role for adrenaline in the formation of traumatic memories has long been postulated (Pitman 1989) . It has been argued that a surge in adrenaline concentration in conjunction with trauma, results in a strong emotional memory and fear conditioning that could prime PTSD. Later human studies supported a role for the beta adrenergic system in memory storing and in the enhanced memories associated with emotional arousal (Cahill 1994; Southwick 1999) , and for propranolol to limit this process (Reist 2001) .
Benzodiazepines
Benzodiazepines are known for reducing arousal and decreasing distress. They have amnesic properties as well, mostly inhibiting memory consolidation by impairing long-term episodic storage (Barbee 1993). Despite this, no clinical research has found a positive effect for benzodiazepines in the management of traumatic stress symptoms (Howlett 2016).
Opioids
Studies on rodents have found retrograde amnesia properties for morphine, and a possible mechanism for that has been proposed via decreasing cyclic adenosine monophosphate or activating Nmethyl-D-aspartate (NMDA) receptors in the hippocampus (McNally 2003) . Human observational studies support a protective effect for morphine (Bryant 2009; Mouthaan 2015) .
Oxytocin
A possible role for oxytocin in the prevention of PTSD is quite a recent approach, which has been proposed on a dual assumption theory: a reduction in the amygdala activation and an increase in the activation of the social reward brain areas (OlC 2010). Behavioural data on rodents seem to confirm a plausible role for oxytocin (Cohen 2010) .
SSRIs
SSRI antidepressants are generally considered the first-line pharmacological treatment for PTSD (ISTSS 2018; NICE 2018) , and might thereby have a putative role in the prevention of the disorder.
Mood stabilisers/anticonvulsants
As for SSRIs, mood stabilisers/anticonvulsants might have a putative role in PTSD prevention, considering their employment as adjuvant/ second-line treatment for anxiety disorders (Van Ameringen 2004) . A trial of gabapentin has been reported in a previous metaanalysis (Stein 2007).
Omega-3 fatty acid compounds
Considering their ability to promote neurogenesis in the hippocampus, a key area in memory consolidation and fear maintenance, a role has been proposed for omega-3 fatty acids in PTSD prevention (Matsuoka 2011).
Why it is important to do this review PTSD represents a heavy burden for the people affected, those around them, health systems and society. Findings from the National Vietnam Veterans Longitudinal Study showed that, even after decades, an important share of male war veterans have PTSD (4.5%, 95% confidence interval (CI) 1.7 to 7.3) or subthreshold PTSD symptoms (6.4%, 95% CI 3.0 to 9.7) (Marmar 2015). Moreover, PTSD is associated with poor general health status and unemployment (Zatzick 1997) . Most of the evidence regards psychosocial intervention, among which trauma-focused and exposure-based therapies are the most promising ones, but many of the studies are restricted by small sample sizes and methodological limits (Birur 2017). Despite the abundance of putative biological and clinical risk factors for PTSD and various predictive strategies being tested, e.g. supervised machine learning (Galatzer-Levy 2014; KarstoJ 2015; Kessler 2014), there is currently no effective way to predict who will develop PTSD after a traumatic experience. The biological features of PTSD provide several possible targets for the prevention of PTSD, and encouraging results were found in previous meta-analyses (Amos 2014; Sijbrandij 2015) . Although it would be valuable to have effective interventions for prevention of PTSD, the riskto-benefit ratio needs to be carefully assessed, as drugs will entail possible side effects for all of those receiving them, and not all of the individuals exposed to a trauma will develop PTSD.
It should be noted that very different kinds of pharmacological interventions have been proposed to prevent PTSD onset, but there is a lack of head-to-head trials between them. It is therefore difficult to make an overall comparison and establish a hierarchy, both in terms of efficacy, tolerability and acceptability. It therefore appears of important value to assess pharmacological interventions to prevent the onset of the condition, applying a methodology that allows indirect comparisons.
O B J E C T I V E S
To assess the efficacy and acceptability of pharmacological interventions for preventing post-traumatic stress disorder (PTSD) in adults exposed to a traumatic event and to generate a clinically useful ranking of pharmacological interventions according to their efficacy and acceptability by performing a network metaanalysis.
M E T H O D S Criteria for considering studies for this review Types of studies
We will include randomised controlled trials (RCTs) comparing one medication with placebo or one medication with another. We will consider trials for inclusion irrespective of language or publication status. For cross-over trials, we will consider the data from the first randomised phase only.
Types of participants Individuals
We will include trials on individuals with all of the following characteristics.
• History of any traumatic event • Aged 18 and older We will exclude studies targeting symptomatic patients at baseline, as these studies will be included in a second parallel review on early interventions, while the present review is on prevention.
Setting
We will consider trials performed in any type of setting.
Subset data
We will include trials in which only a portion of the sample meets the above criteria, provided that the relevant data can be gained from the study report or by contacting the authors, and that the effect of randomisation is not affected by doing so.
Types of interventions
The Diagnostic and Statistical Manual of Mental Disorders, FiJh Edition (DSM-5) regards the three months from the trauma as a relevant timeframe for symptoms' evolution (APA 2013). We will then consider any pharmacological intervention administered with the intention to prevent the onset of post-traumatic stress disorder (PTSD) or PTSD symptoms within such a timeframe. We will set no restriction regarding dose, duration, administration route of the intervention, nor on the presence of any co-medication not related to PTSD prevention. We will not consider trials where the experimental medication was used as an augmentation agent to ongoing psychotherapy (e.g. cognitive enhancers).
Based on our knowledge of the literature, we expect drugs from the following pharmacological groups to be found.
• Glucocorticoids • Beta-blockers • Benzodiazepines • Opioids • Other hormones (oxytocin) • Selective serotonin reuptake inhibitors (SSRIs) • Mood stabilisers/anticonvulsants • Omega-3 fatty acid compounds
We assume that any individual that meets the inclusion criteria is, in principle, equally likely to be randomised to any of the eligible interventions.
We will include any other pharmacological interventions we might find during the review process and clearly report them. We will consider them eligible for the network meta-analysis after assessing their comparability with the before mentioned prespecified set of competing interventions, in order to preserve the assumption of 'jointly randomisable' treatments.
Types of comparison
We will include studies using both placebo and any active pharmacological comparison. We will not consider studies comparing pharmacological interventions with only psychosocial interventions (i.e. with no other pharmacological or placebo arm).
We will include studies that meet the above criteria, irrespective of whether they report any of our outcomes of interest.
Types of outcome measures Primary outcomes
• PTSD severity (continuous): we will use the mean score on the Clinician-Administered PTSD Scale (CAPS) (Blake 1995), or the Comprehensive International Diagnostic Interview (CIDI) (WHO 1997), or any other validated rating scale to assess symptom severity.
• Dropouts due to adverse events (dichotomous): we will consider the number of participants who leave the assigned arm early due to side effects, out of the number of randomised individuals. Secondary outcomes • PTSD rate (dichotomous): we will consider PTSD rates, as measured by a DSM or International Classification of Diseases (ICD) (WHO 1992) diagnosis made with a clinician-administered measure. • Dropout for any reason (dichotomous): we will consider the number of participants who leave the assigned arm early for any reason, out of the number of randomised individuals.
Hierarchy of outcome measures
The hierarchy of outcome measure scales will follow the order above. As we expect that clinician-administered scales to have been more frequently employed, in case of trials employing validated scales different from the before mentioned, for homogeneity reasons we will give priority to clinician-administered scales over selfreported ones.
Timing of outcome measures
We will synthesise data at three months follow-up (i.e. 3 months after experiencing trauma), operationalised as the time point closest to three months of follow-up (from 2 to 4 months of follow-up). In addition, we will include data at study endpoint as a secondary time point.
Search methods for identification of studies Specialised register: the Cochrane Common Mental Disorders Controlled Trials Register (CCMDCTR)
Cochrane Common Mental Disorders (CCMD) maintained a specialised register of randomised controlled trials (RCTs), the CCMDCTR, to June 2016. This register contains over 40,000 reference records (reports of RCTs) for anxiety and depressive disorders, bipolar disorder, eating disorders, self-harm and other mental disorders within the scope of CCMD. The CCMDCTR is a partially studies-based register with > 50% of the reference records tagged to 12,600 individually participant, intervention, comparison, outcome (PICO)-coded study records. Reports of trials for inclusion in the register were collated from (weekly) generic searches of MEDLINE (1950-), Embase (1974-) and PsycINFO (1967-) , quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL) and review-specific searches of additional databases. Reports of trials were also sourced from international trial registries, drug companies, handsearching of key journals, conference proceedings and other (non-Cochrane) systematic reviews and metaanalyses. Details of CCMD's core search strategies (used to identify RCTs) can be found on CCMD's website, with an example of the MEDLINE search displayed in Appendix 2. The register fell out-of date with the relocation of the group from the University of Bristol to York University in June 2016.
Electronic searches CCMDCTR-studies and references register
We will cross-search the CCMDCTR studies and references register for condition alone, using the following terms: (PTSD or posttrauma* or post-trauma* or "post trauma*" or "combat disorder*" or "stress disorder*") (all years to June 2016). We will screen the search results for any pharmacological intervention (active intervention versus placebo or active intervention versus active intervention trials) to prevent the onset of PTSD.
Biomedical database search
We will search Ovid MEDLINE, Embase and PsycINFO, Ebsco Published International Literature On Traumatic Stress (PILOTS) and the Cochrane Central Register of Controlled Trials (CENTRAL) from 2014 onwards. This is to account for the period when the CCMDCTR fell out-of-date. A search has already been conducted by the CCMD editorial base (3 March 2018) (Appendix 3). We will screen the results of this search for all relevant pharmacological RCTs to prevent the onset of PTSD.
International trials registers
We will search for unpublished studies in international trials registers via the World Health Organization's trials portal (ICTRP), and the National Institute of Health's trials website (clinicaltrials.gov). See Appendix 4 for search strategies on these sources. We will not apply any publication status or language restrictions. We will re-run all searches close to publication if the initial search date is greater than 12 months.
Searching other resources
We will check the reference list of all included studies and relevant systematic reviews.
Data collection and analysis Selection of studies
We will import all records obtained via the electronic search, plus the handsearch, into Endnote software (EndNote) in order to remove all duplicates. Two review authors (FB and LR) will work in duplicate and independently. They will screen all potential papers' titles and abstracts and code them as 'retrieve' or 'not retrieve', obtain the full-text publication of the records coded as 'retrieve', and assess inclusion and exclusion criteria. Disagreement will be resolved by discussion or, if necessary, by involving a third review author (NM). We will record the selection process in sufficient detail to complete a PRISMA flow diagram and 'Characteristics of excluded studies' table (Moher 2009). Data extraction and management Two review authors (FB and LR) working independently and in duplicate will extract data from the included trials. We will use a data extraction sheet developed in accordance with the Cochrane Handbook for Systematic Reviews of Interventions section 7.5 (Higgins 2011). We will collect the following data.
• First author, year of publication, journal, source of funding, notable conflict of interest of authors, total duration of study, number of centres and location.
• Methodological characteristics of the trial: randomisation, blinding, allocation concealment, number of arms, follow-up time points.
• Sample characteristics: study setting, type of trauma, criteria for enrolling, age, gender, number of participants randomised to each arm, history of previous trauma. • Intervention details: time from the traumatic event to treatment, medication employed, period over which it has been administered, dosage range, mean dosage prescribed. • Outcomes: time points of outcome assessment, instrument used to assess PTSD symptoms, instrument used to assess PTSD rate, instrument used to assess depression symptoms, instrument used to assess anxiety, instrument used to assess functional disability, outcome measure employed by original trial (primary and secondary), data of continuous (means and standard deviation or standard error if standard deviation is not provided) and dichotomous variables of interest, number of total dropouts, number of dropouts due to pharmacological side effect, whether the data reflect an intention-to-treat (ITT) model, methods of estimating the outcome for participants who dropped out (last observation carried forward (LOCF) or completer/observed case (OC) approach, or other).
Assessment of risk of bias in included studies
Two review authors (FB and LR) working independently and in duplicate will assess risk of bias for each study according to the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). Disagreement will be resolved by discussion, or if necessary by involving a third review author (NM). We will assess the risk of bias according to the following domains. 1. Random sequence generation (selection bias) 2. Allocation concealment (selection bias) 3. Blinding of participants and personal (performance bias) 4. Blinding of outcome assessment (detection bias) 5. Incomplete outcome data (attrition bias) 6. Selective reporting (reporting bias) 7. Other bias
We will assess performance, detection and attrition bias on a per outcome basis rather than per study. We will rate each source of bias as high, low or unclear. We will provide reasons to justify therating. We will present all data regarding risk of bias both graphically and in the text.
Measures of treatment effect Dichotomous data
For dichotomous data, we will calculate risk ratio (RR) estimates and their 95% confidence interval (CI). RRs are more easily interpreted than odds ratios (ORs) (Boissel 1999), and as clinicians may risk interpreting ORs as RRs (Deeks 2002) , this may lead to an over-estimation of the effect. We will calculate the number needed to treat to benefit (NNTB).
Continuous data
For continuous data, we will calculate the mean differences (MDs)and the 95% CI, where data are measured on the same scale. If the studies employed different scales, we will use standardised mean differences (SMDs). The trials may report the results either as end point means or using change in mean values from baseline assessment. Preference will be given to endpoint measures, given the nature of the review (prevention) and that endpoint data are easier to interpret from a clinical point of view. Where sufficient data are reported, we will convert change scores into endpoint data using standard formulas reported in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We will interpret SMDs according to the following guidelines: 0.2 represents a small effect,0.5 a moderate effect, and 0.8 a large effect (Cohen 1988) .
Unit of analysis issues Crossover trials
We will consider only the first phase from cross-over trials as the carry over effect cannot be excluded on a prevention measure, regardless of appropriate washout times. Cluster randomised trials If cluster-RCTs are included, but have not appropriately adjusted for the correlation between participants within clusters, we will contact trial authors to obtain an estimate of the intra cluster correlation (ICC), or impute using estimates from the other included trials or from similar external trials. If imputation of ICCs is required, we will conduct sensitivity analyses to examine the impact on estimates.
Multiple treatment group studies
For the pair-wise meta-analysis, we will compare each arm with placebo separately and include each pair-wise comparison separately. We plan the following means to prevent 'double-counting', in accordance with the Cochrane Handbook for Systematic Reviews of Interventions, section 16.5.4 (Higgins 2011): in the case of dichotomous variables, we will split the comparison group evenly among the intervention groups, in the case of continuous variables, we will only divide the total number of participants and leave the mean and SDs unchanged. For the network meta-analyses, we will adjust for correlations inherent in multiple-arm trials using standard methods (e.g. Dias2013a).
Dose-ranging studies
If a study has multiple arms with the same medication administered at different doses or administered for a different time length, we will pool these intervention groups into a single one, as recommended by the Cochrane Handbook for Systematic Reviews of Interventions, section 16.5.4 (Higgins 2011).
Dealing with missing data
As a first measure, we will contact study investigators to obtain missing data. Should this not be effective, we will employ the following approaches.
Dichotomous data
Where reported, we will use ITT data analysed on a 'once randomised, always randomised' basis. In case of trials conducting different imputational strategies, we will give preference to data de-rived from multiple imputation or mixed-effects models. For studies that did not perform an ITT analysis, we will assume a negative outcome (i.e. onset of PTSD) for individuals lost at follow-up.
Continuous data
As above, we will use ITT data where reported, and favour multiple imputation or mixed-effects models where different imputationals trategies have been used. In the context of prevention, last observation carried forward (LOCF) provides the least conservative option and therefore observed case (OC) data will be preferred. For studies not reporting ITT analyses, we will not impute missing data for continuous outcomes, as this usually requires access to individual participant data. We will report, in the relevant section of the results, if the data employed were based on an imputational method and if so, which one.
Missing statistics
Where possible, we will calculate SDs when only P values, CIs, standard errors etc. are reported. If this is not be possible, we will calculate an arithmetic mean of the SDs of studies using the same scale of the one with missing SD, as in Furukawa 2006.
Assessment of heterogeneity
We will assess heterogeneity by means of: •visual inspection on the overlap of the CIs for individual studies in the forest plot; •Chi2 test, with a P value set at 0.10 (we presume the number of studies to be small); •I2 statistic: in accordance with the suggestion in the Cochrane Handbook for Systematic Reviews of Interventions section 9.5.2(Higgins 2011), we will follow a rough guide to interpretation as follows: 0% to 40%: might not be important; 30% to 60%: may represent moderate heterogeneity; 50% to 90%: may represent substantial heterogeneity; 75% to 100%: considerable heterogeneity. We will also take into account magnitude and direction of effects.
Assessment of reporting biases
If more then 10 studies are included per primary outcome, we will: •visually inspect the relative funnel plots, test them for asymme-try and investigate possible reasons for funnel plot asymmetry; •employ Egger's regression test (Egger 1997) .
Data synthesis Methods for pair-wise meta-analysis
We will perform standard pair-wise meta-analysis with a random-effects model for every comparison with at least two studies, using Review Manager 5 (Review Manager 2014). Given the nature of the data, and the likely heterogeneity, we think a random-effects model makes more plausible assumptions. We will perform the pairwise comparison at individual medicine level (e.g. propranolol versus placebo), but if this is not feasible due to the number of studies, we will shift to drug class level (e.g. Beta blocking agents versus placebo), using the WHO's Anatomical Therapeutic Chemical (ATC) / Defined Daily Dose (DDD) Index 2019 as a reference (WHO2018). We will not perform a pair-wise meta-analysis in the case of comparisons with less than two contributing trials. Methods for network meta-analysis For primary outcomes, at both time points (3 months from trauma and at study endpoint), we will assess if there are sufficient data to perform a network meta-analysis. If there are sufficient data, we will perform a network meta-analysis using Markov Chain MonteCarlo methods. We will fit random-effects models in a Bayesian framework using WinBUGS/OpenBUGS (WinBUGS 2000), with standard code (Dias 2013a).
